Yondelis (trabectedin)
- Region
- 🇪🇺 EU
- Active substance
- trabectedin
- Company
- Pharma Mar S.A.
- Status
- Refused
- Therapeutic area
- Sarcoma
- CHMP opinion
- Thu 20 Nov 2003
- Application
- EMEA/H/C/000464
- ATC
- L01CX01
- Official record
- www.ema.europa.eu
Indication
Yondelis is indicated for the treatment of patients with advanced soft tissue sarcoma, having failed antracyclines and ifosfamide, or having failed ifosfamide and unsuitable to receive antracyclines/ifosfamide.
Regulatory milestones
No milestones recorded in the last year.
Same substance in other markets
- 🇪🇺 Yondelis Authorised · Pharma Mar S.A.
- 🇺🇸 Trabectedin Approved · Ever
- 🇪🇺 Trabectedin Accord Authorised · Accord Healthcare S.L.U.
- 🇺🇸 Evdi Approved · Apotex
Follow Yondelis
Get VigiEye Daily: approvals, opinions, safety actions and PDUFA dates every morning.
Information from official EMA, FDA, Federal Register and SEC records. Dates marked company-announced come from the company's own SEC filing; dates marked estimate are calculated, not official. Not investment or medical advice; always confirm on the source.